Prime Medicine, Inc.
PRME
Key stats
- Open
- 4.04
- Day high
- 4.15
- Day low
- 3.73
- Previous close
- 4.30
- Volume
- 7.17M
- VWAP
- 3.91
- 52-week high
- 5.91
- 52-week low
- 2.67
- Market cap
- 779.92M
- Shares out
- 181.38M
- Employees
- 146
- Listed
- 2022
About Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CAMBRIDGE, MA · primemedicine.com
Options · expiring Nov 20
Nov 12, 3:59 PM ET- Call open interest
- 7.7K
- Put open interest
- 2.7K
- Put/call
- 0.36
- At-the-money IV
- 141.0%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 3.50 put | 0.20 | Nov 11, 10:09 AM | 500 | 512 | 181.1% |
| 4.50 call | 0.05 | Nov 12, 3:35 PM | 414 | 759 | 149.8% |
| 4 put | 0.25 | Nov 12, 2:46 PM | 102 | 727 | 159.7% |
| 5 call | 0.10 | Nov 12, 1:58 PM | 69 | 5.0K | 162.0% |
| 4 call | 0.25 | Nov 12, 11:26 AM | 19 | 1.8K | 141.0% |
| 3 call | 1.00 | Nov 12, 11:28 AM | 5 | 74 | 174.7% |
Quarterly results
Massive · Aug 6, 2026| Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | Q3 2025 to Sep 30, 2025 | |
|---|---|---|---|---|
| Revenue | $1.15M | $856.0K | $838.0K | $1.23M |
| Gross profit | $1.15M | $856.0K | $838.0K | $1.23M |
| Operating income | −$43.28M | −$50.65M | −$48.61M | −$53.97M |
| Net income | −$42.11M | −$49.12M | −$46.08M | −$50.58M |
| Diluted EPS | -0.24 | -0.28 | -0.26 | -0.32 |
| Operating cash flow | −$41.05M | −$42.71M | −$37.26M | −$35.04M |
| Assets | $249.04M | $294.73M | $342.73M | $385.01M |
| Liabilities | $209.23M | $218.03M | $221.87M | $223.19M |
| Equity | $39.81M | $76.70M | $120.87M | $161.82M |
Technicals
Massive · Nov 12, 2026- 50-day average3.69
- 200-day average3.50
- RSI (14 days)47.5
Short interest
Massive · Oct 30, 2026- Oct 30, 202629.15M shares · 4.8 days to cover
- Oct 15, 202632.87M shares · 5.5 days to cover
- Sep 30, 202632.12M shares · 8.4 days to cover
- Sep 15, 202632.13M shares · 12.3 days to cover
Dividends
Massive · Sep 10, 2019- Ex Sep 10, 2019, paid Sep 12, 20190.8000 · 4 a year
- Ex Jun 14, 2019, paid Jun 28, 20190.2000 · 4 a year
- Ex Dec 18, 2018, paid Dec 31, 20180.2133 · 4 a year
- Ex Sep 14, 2018, paid Sep 28, 20180.2327 · 4 a year
- Ex Jun 21, 2018, paid Jun 29, 20180.1457 · 4 a year
- Ex Mar 22, 2018, paid Mar 29, 20180.0061 · 4 a year
- Ex Dec 21, 2017, paid Dec 29, 20170.8613 · 4 a year
- Ex Sep 21, 2017, paid Sep 29, 20170.0660 · 4 a year
Related companies
MassiveNews coverage
No stories about Prime Medicine, Inc. right now.